.Merck & Co.'s TIGIT program has endured an additional setback. Months after shuttering a period ...
.After a year specified through pipeline cuts, the departure of its chief executive officer and layo...
.Cullinan Therapy was actually excited sufficient with Harbour BioMed's bispecific invulnerable acti...
.In this week's incident of "The Best Line," we are actually diving right into Tough Biotech's yearl...
.The confetti is still flying from Eli Lilly's event celebrating the approval of Alzheimer's disease...
.Welcome to today's Chutes & Ladders, our roundup of considerable leadership hirings, firings as ...
.Complying with a poor presenting for Lykos Therapies' MDMA candidate for post-traumatic stress diso...
.AN2 Therapies is actually reassessing its company in response to lackluster midphase records, swear...
.Merck & Co. is actually paying $700 thousand ahead of time to challenge Amgen in a blood stream ...
.With Gilead Sciences almost an FDA selection for its liver illness medicine seladelpar, the provide...